Skip to main content
SpringerLink
Log in
Book cover

Delta Opioid Receptor Pharmacology and Therapeutic Applications pp 53–70Cite as

Contribution of Delta-Opioid Receptors to Pathophysiological Events Explored by Endogenous Enkephalins

  • Chapter
  • First Online:

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 247))

Abstract

Very few discoveries in the neurosciences have triggered clinical speculation and experimentation regarding the etiology of psychiatric illness to the same extent as that following identification of the opiate receptor(s) and subsequent isolation of endogenous morphine-like peptides. There is overwhelming evidence in animals and in human that opioids are involved in behaviorally relevant issues such as the modulation of pain, the response to stress, motivation, addiction, sexuality, food intake, etc., but our knowledge on the possible relation between opioids and mental illness is still very limited.

These responses could be explored either by using highly selective delta agonist or by emphasizing the effects of phasically secreted endogenous opioid peptides, enkephalin. Both approaches were investigated in particular through protection of enkephalin degradation by dual enkephalinase inhibitors DENKIs such as RB101, PL37 or PL265.

This is a preview of subscription content, log in via an institution.

Change history

  • 16 July 2019

    The book was inadvertently published with error in the following chapters.

References

  • Agmo A, Galvan A, Talamantes B (1995) Reward and reinforcement produced by drinking sucrose: two processes that may depend on different neurotransmitters. Pharmacol Biochem Behav 52:403–414

    Article  CAS  PubMed  Google Scholar 

  • Baamonde A, Dauge V, Ruiz-Gayo M, Fulga IG, Turcaud S, Fournie-Zaluski MC, Roques BP (1992) Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation. Eur J Pharmacol 216:157–166

    Article  CAS  PubMed  Google Scholar 

  • Baik JH, Picetti R, Saiardi A, Thiriet G, Dierich A, Depaulis A, Le Meur M, Borrelli E (1995) Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377:424–428

    Article  CAS  PubMed  Google Scholar 

  • Benoist JM, Keime F, Montagne J, Noble F, Fournie-Zaluski MC, Roques BP, Willer JC, Le Bars D (2002) Depressant effect on a C-fibre reflex in the rat, of RB101, a dual inhibitor of enkephalin-degrading enzymes. Eur J Pharmacol 445:201–210

    Article  CAS  PubMed  Google Scholar 

  • Bertrand E, Smadja C, Mauborgne A, Roques BP, Daugé V (1997) Social interaction increases the extracellular levels of [Met]enkephalin in the nucleus accumbens of control but not of chronic mild stressed rats. Neuroscience 80:17–20

    Article  CAS  PubMed  Google Scholar 

  • Bodkin JA, Zornberg GL, Lukas SE, Cole JO (1995) Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 15:49–57

    Article  CAS  PubMed  Google Scholar 

  • Bonnard E, Poras H, Nadal X, Maldonado R, Fournie-Zaluski MC, Roques BP (2015) Long-lasting oral analgesic effects of N-protected aminophosphinic dual ENKephalinase inhibitors (DENKIs) in peripherally controlled pain. Pharmacol Res Perspect 3:e00116

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Bourgoin S, Le Bars D, Artaud F, Clot AM, Bouboutou R, Fournie-Zaluski MC, Roques BP, Hamon M, Cesselin F (1986) Effects of kelatorphan and other peptidase inhibitors on the in vitro and in vivo release of methionine-enkephalin-like material from the rat spinal cord. J Pharmacol Exp Ther 238:360–366

    CAS  PubMed  Google Scholar 

  • Bozarth MA (1991) The mesolimbic dopamine system as a model reward system. In: Willner P, Scheel-Krüger J (eds) The mesolimbic dopamine system : from motivation to action. Wiley, New York, pp 301–330

    Google Scholar 

  • Calenco-Choukroun G, Dauge V, Gacel G, Feger J, Roques BP (1991a) Opioid delta agonists and endogenous enkephalins induce different emotional reactivity than mu agonists after injection in the rat ventral tegmental area. Psychopharmacology (Berl) 103:493–502

    Article  CAS  Google Scholar 

  • Calenco-Choukroun G, Dauge V, Gacel G, Roques BP (1991b) Lesion of dopamine mesolimbic neurons blocks behavioral effects induced by the endogenous enkephalins but not by a mu-opioid receptor agonist. Eur J Pharmacol 209:267–271

    Article  CAS  PubMed  Google Scholar 

  • Chu Sin Chung P, Keyworth HL, Martin-Garcia E, Charbogne P, Darcq E, Bailey A, Filliol D, Matifas A, Scherrer G, Ouagazzal AM, Gaveriaux-Ruff C, Befort K, Maldonado R, Kitchen I, Kieffer BL (2015) A novel anxiogenic role for the delta opioid receptor expressed in GABAergic forebrain neurons. Biol Psychiatry 77:404–415

    Article  CAS  PubMed  Google Scholar 

  • Cordonnier L, Sanchez M, Roques BP, Noble F (2005) Facilitation of enkephalins-induced delta-opioid behavioral responses by chronic amisulpride treatment. Neuroscience 135:1–10

    Article  CAS  PubMed  Google Scholar 

  • Darko DF, Risch SC, Gillin JC, Golshan S (1992) Association of beta-endorphin with specific clinical symptoms of depression. Am J Psychiatry 149:1162–1167

    Article  CAS  PubMed  Google Scholar 

  • Dauge V, Rossignol P, Roques BP (1988) Comparison of the behavioural effects induced by administration in rat nucleus accumbens or nucleus caudatus of selective mu and delta opioid peptides or kelatorphan an inhibitor of enkephalin-degrading-enzymes. Psychopharmacology (Berl) 96:343–352

    Article  CAS  Google Scholar 

  • Daugé V, Rossignol P, Roques BP (1989) Blockade of dopamine receptors reverses the behavioral effects of endogenous enkephalins in the nucleus caudatus but not in the nucleus accumbens : involvement of ∂ and μ opioid receptors. Psychopharmacology (Berl) 99:168–175

    Article  Google Scholar 

  • Dauge V, Kalivas PW, Duffy T, Roques BP (1992) Effect of inhibiting enkephalin catabolism in the VTA on motor activity and extracellular dopamine. Brain Res 599:209–214

    Article  CAS  PubMed  Google Scholar 

  • De Felipe MC, De Ceballos ML, Gil C, Fuentes JA (1985) Chronic antidepressant treatment increases enkephalin levels in n. accumbens and striatum of the rat. Eur J Pharmacol 112:119–122

    Article  PubMed  Google Scholar 

  • Delay-Goyet P, Zajac JM, Roques BP (1990) Improved quantitative radioautography of rat brain ∂-opioid binding sites using [(3)H]DSTBULET, a new highly potent and selective linear enkephalin analogue. Neurochem Int 16:341–368

    Article  CAS  PubMed  Google Scholar 

  • Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85:5274–5278

    Article  PubMed  PubMed Central  Google Scholar 

  • Djurovic D, Milic-Askrabic J, Majkic-Singh N (1999) Serum beta-endorphin level in patients with depression on fluvoxamine. Farmaco 54:130–133

    Article  CAS  PubMed  Google Scholar 

  • Emrich HM, Hollt V, Kissling W, Fischler M, Laspe H, Heinemann H, von Zerssen D, Herz A (1979) beta-Endorphin-like immunoreactivity in cerebrospinal fluid and plasma of patients with schizophrenia and other neuropsychiatric disorders. Pharmakopsychiatr Neuropsychopharmakol 12:269–276

    Article  CAS  PubMed  Google Scholar 

  • Erbs E, Paget L, Scherrer G, Matifas A, Filliol D, Vonesch JL, Koch M, Kessler P, Hentsch D, Birling MC, Koutsourakis M, Vasseur, Veinante P, Kieffeter BL, Massotte D (2015) A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks. Brain Struct Funct 220:677–702

    Article  PubMed  CAS  Google Scholar 

  • Evans CJ, Keith DE Jr, Morrison H, Magendzo K, Edwards RH (1992) Cloning of a delta opioid receptor by functional expression. Science 258:1952–1955

    Article  CAS  PubMed  Google Scholar 

  • Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gaveriaux-Ruff C, Dierich A, LeMeur M, Valverde O, Maldonado R, Kieffer BL (2000) Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25:195–200

    Article  CAS  PubMed  Google Scholar 

  • Fournie-Zaluski MC, Roques BP (2002) New selective aminopeptidase N inhibitors and potential therapeutic. In: Langner J, Snyder A (eds) Ectopeptidases : CD13/Aminopeptidase N and CD26/Dipeptidyl peptidase IV in medicine and biology. Kluwer Academic/Plenum Publishers, New York, pp 51–94

    Chapter  Google Scholar 

  • Fournie-Zaluski MC, Chaillet P, Bouboutou R, Coulaud A, Cherot P, Waksman G, Costentin J, Roques BP (1984) Analgesic effects of kelatorphan, a new highly potent inhibitor of multiple enkephalin degrading enzymes. Eur J Pharmacol 102:525–528

    Article  CAS  PubMed  Google Scholar 

  • Fournie-Zaluski MC, Coulaud A, Bouboutou R, Chaillet P, Devin J, Waksman G, Costentin J, Roques BP (1985) New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties. J Med Chem 28:1158–1169

    Article  CAS  PubMed  Google Scholar 

  • Fournie-Zaluski MC, Coric P, Turcaud S, Lucas E, Noble F, Maldonado R, Roques BP (1992) “Mixed inhibitor-prodrug” as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes. J Med Chem 35:2473–2481

    Article  CAS  PubMed  Google Scholar 

  • Fournie-Zaluski MC, Poras H, Roques BP, Nakajima Y, Ito K, Yoshimoto T (2009) Structure of aminopeptidase N from Escherichia coli complexed with the transition-state analogue aminophosphinic inhibitor PL250. Acta Crystallogr D Biol Crystallogr 65:814–822

    Article  CAS  PubMed  Google Scholar 

  • Gonzalez-Rodriguez S, Pevida M, Roques BP, Fournie-Zaluski MC, Hidalgo A, Menendez L, Baamonde A (2009) Involvement of enkephalins in the inhibition of osteosarcoma-induced thermal hyperalgesia evoked by the blockade of peripheral P2X3 receptors. Neurosci Lett 465:285–289

    Article  CAS  PubMed  Google Scholar 

  • Gonzalez-Rodriguez S, Menendez L, Lastra A, Baamonde A, Roques BP, Fournié-Zaluski MC, Poras H (2015) Antihyperalgesic effects of PL265, an orally active dual enkephalinase inhibitor (DENKI) in a mice model of tibial bone cancer and synergistic responses when combined with gabapentin, the purinergic antagonist □-317491 or a cannabinoid CB2 agonist. In preparation

    Google Scholar 

  • Groenewegen HJ, Berendse HW, Meredith GE, Haber SN, Voorn P, Woters JG, Lohman AHM (1991) Functional anatomy of the ventral, limbic system-innervated striatum. In: Willner P, Scheel-Krüger J (eds) The mesolimbic dopamine system: from motivation to action. Wiley, New York, pp 19–59

    Google Scholar 

  • Heidbreder C, Roques B, Vanderhaeghen JJ, De Witte P (1988) Kelatorphan, a potent enkephalinases inhibitor, presents opposite properties when injected intracerebroventricularly or into the nucleus accumbens on intracranial self-stimulation. Neurochem Int 12:347–350

    Article  CAS  PubMed  Google Scholar 

  • Hollister LE, Johnson K, Boukhabza D, Gillespie HK (1981) Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend 8:37–41

    Article  CAS  PubMed  Google Scholar 

  • Hong JS, Yang HY, Fratta W, Costa E (1978) Rat striatal methionine-enkephalin content after chronic treatment with cataleptogenic and noncataleptogenic antischizophrenic drugs. J Pharmacol Exp Ther 205:141–147

    CAS  PubMed  Google Scholar 

  • Inturrisi CE, Alexopoulos G, Lipman R, Foley K, Rossier J (1982) beta-Endorphin immunoreactivity in the plasma of psychiatric patients receiving electroconvulsive treatment. Ann N Y Acad Sci 398:413–423

    Article  CAS  PubMed  Google Scholar 

  • Jaber M, Tison F, Fournier MC, Bloch B (1994) Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary. Brain Res Mol Brain Res 23:14–20

    Article  CAS  PubMed  Google Scholar 

  • Jardinaud F, Banisadr G, Noble F, Melik-Parsadaniantz S, Chen H, Dugave C, Laplace H, Rostene W, Fournie-Zaluski MC, Roques BP, Popovici T (2004) Ontogenic and adult whole body distribution of aminopeptidase N in rat investigated by in vitro autoradiography. Biochimie 86:105–113

    Article  CAS  PubMed  Google Scholar 

  • Jardinaud F, Crete D, Canestrelli C, Ledent C, Roques BP, Noble F (2005) CB1 receptor knockout mice show similar behavioral modifications to wild-type mice when enkephalin catabolism is inhibited. Brain Res 1063:77–83

    Article  CAS  PubMed  Google Scholar 

  • Kalivas PW, Bronson M (1985) Mesolimbic dopamine lesions produce an augmented behavioral response to enkephalin. Neuropharmacology 24:931–936

    Article  CAS  PubMed  Google Scholar 

  • Kalivas PW, Widerlov E, Stanley D, Breese G, Prange AJ Jr (1983) Enkephalin action on the mesolimbic system: a dopamine-dependent and a dopamine-independent increase in locomotor activity. J Pharmacol Exp Ther 227:229–237

    CAS  PubMed  Google Scholar 

  • Kayser V, Fournie-Zaluski MC, Guilbaud G, Roques BP (1989) Potent antinociceptive effects of kelatorphan (a highly efficient inhibitor of multiple enkephalin-degrading enzymes) systemically administered in normal and arthritic rats. Brain Res 497:94–101

    Article  CAS  PubMed  Google Scholar 

  • Kennedy SE, Koeppe RA, Young EA, Zubieta JK (2006) Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 63:1199–1208

    Article  CAS  PubMed  Google Scholar 

  • Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG (1992) The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci U S A 89:12048–12052

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kline NS, Li CH, Lehmann HE, Lajtha A, Laski E, Cooper T (1977) Beta-endorphin--induced changes in schizophrenic and depressed patients. Arch Gen Psychiatry 34:1111–1113

    Article  CAS  PubMed  Google Scholar 

  • Konig M, Zimmer AM, Steiner H, Holmes PV, Crawley JN, Brownstein MJ, Zimmer A (1996) Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383:535–538

    Article  CAS  PubMed  Google Scholar 

  • Kung JC, Chen TC, Shyu BC, Hsiao S, Huang AC (2010) Anxiety- and depressive-like responses and c-fos activity in preproenkephalin knockout mice: oversensitivity hypothesis of enkephalin deficit-induced posttraumatic stress disorder. J Biomed Sci 17:29

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Le Merrer J, Becker JA, Befort K, Kieffer BL (2009) Reward processing by the opioid system in the brain. Physiol Rev 89:1379–1412

    Article  PubMed  Google Scholar 

  • Le Moine C, Bloch B (1995) D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive mRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J Comp Neurol 355:426–481

    Article  Google Scholar 

  • Le Moine C, Normand E, Bloch B (1991) Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene. Proc Natl Acad Sci U S A 88:4206–4209

    Article  Google Scholar 

  • Lee SH, Kayser V, Guilbaud G (1994) Antinociceptive effect of systemic kelatorphan, in mononeuropathic rats, involves different opioid receptor types. Eur J Pharmacol 264:61–67

    Article  CAS  PubMed  Google Scholar 

  • MacLennan AJ, Maier SF (1983) Coping and the stress-induced potentiation of stimulant stereotypy in the rat. Science 219:1091–1093

    Article  CAS  PubMed  Google Scholar 

  • Madar I, Lever JR, Kinter CM, Scheffel U, Ravert HT, Musachio JL, Mathews WB, Dannals RF, Frost JJ (1996) Imaging of delta opioid receptors in human brain by N1’-([11C]methyl)naltrindole and PET. Synapse 24:19–28

    Article  CAS  PubMed  Google Scholar 

  • Maldonado R, Dauge V, Feger J, Roques BP (1990) Chronic blockade of D2 but not D1 dopamine receptors facilitates behavioural responses to endogenous enkephalins, protected by kelatorphan, administered in the accumbens in rats. Neuropharmacology 29:215–223

    Article  CAS  PubMed  Google Scholar 

  • Maldonado R, Valverde O, Turcaud S, Fournie-Zaluski MC, Roques BP (1994) Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation. Pain 58:77–83

    Article  CAS  PubMed  Google Scholar 

  • Maldonado R, Saiardi A, Valverde O, Samad TA, Roques BP, Borrelli E (1997) Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 388:586–589

    Article  CAS  PubMed  Google Scholar 

  • Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1988) Anatomy of CNS opioid receptors. Trends Neurosci 11:308–314

    Article  CAS  PubMed  Google Scholar 

  • Marie-Claire C, Tiraboschi G, Ruffet E, Inguimbert N, Fournie-Zaluski MC, Roques BP (2000) Exploration of the S(')(1) subsite of neprilysin: a joined molecular modeling and site-directed mutagenesis study. Proteins 39:365–371

    Article  CAS  PubMed  Google Scholar 

  • Mas-Nieto M, Pommier B, Tzavara ET, Caneparo A, Da Nascimento S, Le Fur G, Roques BP, Noble F (2001) Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol 132:1809–1816

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • McNally GP (2005) Facilitation of fear extinction by midbrain periaqueductal gray infusions of RB101(S), an inhibitor of enkephalin-degrading enzymes. Behav Neurosci 119:1672–1677

    Article  CAS  PubMed  Google Scholar 

  • Menendez L, Hidalgo A, Meana A, Poras H, Fournie-Zaluski MC, Roques BP, Baamonde A (2008) Inhibition of osteosarcoma-induced thermal hyperalgesia in mice by the orally active dual enkephalinase inhibitor PL37. Potentiation by gabapentin. Eur J Pharmacol 596:50–55

    Article  CAS  PubMed  Google Scholar 

  • Meynadier J, Dalmas S, Lecomte JM, Gros C, Schwartz JC (1988) Potent analgesic effects of inhibitors of enkephalin metabolism administered intrathecally to cancer patients. Pain Clin 2:201–206

    Google Scholar 

  • Mina-Osorio P (2008) The moonlighting enzyme CD13: old and new functions to target. Trends Mol Med 14:361–371

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Moller HJ (2003) Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1101–1111

    Article  CAS  PubMed  Google Scholar 

  • Muscat R, Willner P (1992) Suppression of sucrose drinking by chronic mild unpredictable stress: a methodological analysis. Neurosci Biobehav Rev 16:507–517

    Article  CAS  PubMed  Google Scholar 

  • Nieto MM, Guen SL, Kieffer BL, Roques BP, Noble F (2005) Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the delta opioid receptors. Neuroscience 135:305–313

    Article  CAS  PubMed  Google Scholar 

  • Noble F, Roques BP (2007) Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs. Expert Opin Ther Targets 11:145–159

    Article  CAS  PubMed  Google Scholar 

  • Noble F, Soleilhac JM, Soroca-Lucas E, Turcaud S, Fournie-Zaluski MC, Roques BP (1992) Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J Pharmacol Exp Ther 261:181–190

    CAS  PubMed  Google Scholar 

  • Normand E, Popovici T, Fellmann D, Bloch B (1987) Anatomical study of enkephalin gene expression in the rat forebrain following haloperidol treatment. Neurosci Lett 83:232–236

    Article  CAS  PubMed  Google Scholar 

  • Normand E, Popovici T, Onteniente B, Fellmann D, Piatier-Tonneau D, Auffray C, Bloch B (1988) Dopaminergic neurons of the substantia nigra modulate preproenkephalin A gene expression in rat striatal neurons. Brain Res 439:39–46

    Article  CAS  PubMed  Google Scholar 

  • Oefner C, Roques BP, Fournie-Zaluski MC, Dale GE (2004) Structural analysis of neprilysin with various specific and potent inhibitors. Acta Crystallogr D Biol Crystallogr 60:392–396

    Article  PubMed  CAS  Google Scholar 

  • Papp M, Muscat R, Willner P (1993) Subsensitivity to rewarding and locomotor stimulant effects of a dopamine agonist following chronic mild stress. Psychopharmacology (Berl) 110:152–158

    Article  CAS  Google Scholar 

  • Perrot S, Kayser V, Fournie-Zaluski MC, Roques BP, Guilbaud G (1993) Antinociceptive effect of systemic PC 12, a prodrug mixed inhibitor of enkephalin-degrading enzymes, in normal and arthritic rats. Eur J Pharmacol 241:129–133

    Article  CAS  PubMed  Google Scholar 

  • Petit F, Hamon M, Fournie-Zaluski MC, Roques BP, Glowinski J (1986) Further evidence for a role of delta-opiate receptors in the presynaptic regulation of newly synthesized dopamine release. Eur J Pharmacol 126:1–9

    Article  CAS  PubMed  Google Scholar 

  • Poras H, Bonnard E, Dange E, Fournié-Zaluski MC, Roques BP (2014) New orally active dual ENKephalinase inhibitors (DENKIs) for central and peripheral pain treatment. J Med Chem 57:5748–5763

    Article  CAS  PubMed  Google Scholar 

  • Pradhan AA, Befort K, Nozaki C, Gaveriaux-Ruff C, Kieffer BL (2011) The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci 32:581–590

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ragnauth A, Schuller A, Morgan M, Chan J, Ogawa S, Pintar J, Bodnar RJ, Pfaff DW (2001) Female preproenkephalin-knockout mice display altered emotional responses. Proc Natl Acad Sci U S A 98:1958–1963

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Roques BP (2000) Novel approaches to targeting neuropeptide systems. Trends Pharmacol Sci 21:475–483

    Article  CAS  PubMed  Google Scholar 

  • Roques BP, Dauge V, Gacel G, Fournie-Zaluski MC (1985) Selective agonists and antagonists of delta-opioid receptors and inhibitors of enkephalins metabolism. Potential use in mental illness. In: Shagass C, Josiassen RC, Bridger WH, Weiss KJ, Stoff D, Simpon GM (eds) Biological psychiatry, developments in psychiatry, vol. 7. Elsevier, New York

    Google Scholar 

  • Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A (1993) Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45:87–146

    CAS  PubMed  Google Scholar 

  • Roques BP, Fournie-Zaluski MC, Wurm M (2012) Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat Rev Drug Discov 11(4):292–310

    Article  CAS  PubMed  Google Scholar 

  • Saitoh A, Yamada M (2012) Antidepressant-like effects of ∂ opioid receptor agonists in animal models. Curr Neuropharmacol 10:231–238

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Scheel-Krüger J, Willner P (1991) The mesolimbic system: principles of operation. In: Willner P, Scheel-Krüger J (eds) The mesolimbic dopamine system: from motivation to action. Wiley, New York, pp 559–597

    Google Scholar 

  • Sesack SR, Pickel VM (1992) Dual ultrastructural localization of enkephalin and tyrosine hydroxylase immunoreactivity in the rat ventral tegmental area: multiple substrates for opiate-dopamine interactions. J Neurosci 12:1335–1350

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Smadja C, Ruiz-Taron F, Turcaud S, Roques BP, Maldonado R (1995) Effects induced by endogenous and exogenous opioids in different animal models of depression: modulation by the CCK system. In: Traynor J (ed) Analgesia, vol 1(4–6). INRC Proceedings 1995, pp 742–745

    Article  Google Scholar 

  • Stamford JA, Muscat R, O'Connor JJ, Patel J, Trout SJ, Wieczorek WJ, Kruk ZL, Willner P (1991) Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine. Psychopharmacology (Berl) 105:275–282

    Article  CAS  Google Scholar 

  • Staunton DA, Deyo SN, Shoemaker WJ, Ettenberg A, Bloom FE (1982) Effects of chronic lithium on enkephalin systems and pain responsiveness. Life Sci 31:1837–1840

    Article  CAS  PubMed  Google Scholar 

  • Stinus L, Winnock M, Kelley AE (1985) Chronic neuroleptic treatment and mesolimbic dopamine denervation induce behavioural supersensitivity to opiates. Psychopharmacology (Berl) 85:323–328

    Article  CAS  Google Scholar 

  • Stinus L, Nadaud D, Jauregui J, Kelley AE (1986) Chronic treatment with five different neuroleptics elicits behavioral supersensitivity to opiate infusion into the nucleus accumbens. Biol Psychiatry 21:34–48

    Article  CAS  PubMed  Google Scholar 

  • Stoll AL, Rueter S (1999) Treatment augmentation with opiates in severe and refractory major depression. Am J Psychiatry 156:2017

    CAS  PubMed  Google Scholar 

  • Tejedor-Real P, Mico JA, Maldonado R, Roques BP, Gibert-Rahola J (1995) Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol Biochem Behav 52:145–152

    Article  CAS  PubMed  Google Scholar 

  • Thanawala V, Kadam VJ, Ghosh R (2008) Enkephalinase inhibitors: potential agents for the management of pain. Curr Drug Targets 9:887–894

    Article  CAS  PubMed  Google Scholar 

  • Tiraboschi G, Jullian N, Thery V, Antonczak S, Fournie-Zaluski MC, Roques BP (1999) A three-dimensional construction of the active site (region 507-749) of human neutral endopeptidase (EC.3.4.24.11). Protein Eng 12:141–149

    Article  CAS  PubMed  Google Scholar 

  • Waksman G, Hamel E, Fournie-Zaluski MC, Roques BP (1986) Autoradiographic comparison of the distribution of the neutral endopeptidase “enkephalinase” and of mu and delta opioid receptors in rat brain. Proc Natl Acad Sci U S A 83:1523–1527

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Willner P, Towell A, Sampson D, Sophokleous S, Muscat R (1987) Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 93:358–364

    Article  CAS  Google Scholar 

  • Wood PL, Stotland M, Richard JW, Rackham A (1980) Actions of mu, kappa, sigma, delta and agonist/antagonist opiates on striatal dopaminergic function. J Pharmacol Exp Ther 215:697–703

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Membre de l’Académie des Sciences (France et Europe), U1022 INSERM/UMR 8258 CNRS, Université Paris-Descartes (Paris V), CSO Pharmaleads SAS, 4 Avenue de l’Observatoire, 75006, Paris, France

    Bernard P. Roques

Authors
  1. Bernard P. Roques
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernard P. Roques .

Editor information

Editors and Affiliations

  1. Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, USA

    Emily M. Jutkiewicz

Rights and permissions

Reprints and permissions

Copyright information

© 2016 SpringerInternationalPublishingSwitzerland

About this chapter

Cite this chapter

Roques, B.P. (2016). Contribution of Delta-Opioid Receptors to Pathophysiological Events Explored by Endogenous Enkephalins. In: Jutkiewicz, E. (eds) Delta Opioid Receptor Pharmacology and Therapeutic Applications. Handbook of Experimental Pharmacology, vol 247. Springer, Cham. https://doi.org/10.1007/164_2016_17

Download citation

Publish with us

Policies and ethics

Search

Navigation